胸腺五肽联合培美曲塞及顺铂化疗治疗晚期肺腺癌的近期疗效及免疫状态观察  

Short-term efficacy and immune status observation of thymopentin combined with pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma

作　　者：张山燕 杜迎节 王先国[1] 李宇[1] 田宁 刘然然[2] ZHANG Shanyan;DU Yingjie;WANG Xianguo;LI Yu;TIAN Ning;LIU Ranran(The Second Department of Chemotherapy,Tai'an Cancer Prevention and Treatment Hospital in Shandong Province,Tai'an271000,China;Image Center,Tai'an Cancer Prevention and Treatment Hospital in Shandong Province,Tai'an271000,China)

机构地区：[1]山东省泰安市肿瘤防治院化疗二科,山东泰安271000 [2]山东省泰安市肿瘤防治院影像中心,山东泰安271000

出　　处：《中国现代医生》2020年第5期84-86,共3页China Modern Doctor

摘　　要：目的探讨胸腺五肽联合培美曲塞及顺铂化疗治疗晚期肺腺癌的近期疗效及免疫功能。方法回顾性分析2017年5月~2019年6月在泰安市肿瘤防治院治疗的80例晚期肺腺癌患者,随机分为对照组和观察组,每组40例。观察组采用胸腺五肽联合培美曲塞及顺铂化疗4周期,对照组仅行培美曲塞及顺铂化疗4周期,比较两组间近期疗效及免疫功能的差异。结果观察组与对照组治疗有效率分别为27.5%、20.0%,差异无统计学意义(P>0.05),而两组间疾病控制率及免疫功能比较差异均有统计学意义(P<0.05)。结论胸腺五肽联合培美曲塞及顺铂化疗治疗晚期肺腺癌可以明显增强患者免疫功能,值得临床参考应用。Objective To investigate the short-term efficacy and immune function of thymopentin combined with pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma.Methods 80 patients with advanced lung adenocarcinoma treated in Tai'an Cancer Prevention and Treatment Hospital between May 2017 and June 2019 were analyzed retrospectively.They were randomly divided into control group(n=40)and observation group(n=40).Thymopentin,pemetrexed and cisplatin were used in the observation group for 4 periods,while pemetrexed and cisplatin were used in the control group for 4 periods.The difference of short-term efficacy and immune function between the two groups was compared.Results The effective rates of treatment in the observation group and the control group were 27.5%and 20.0%respectively,and the difference was not statistically significant(P>0.05),but there was significant difference in disease control rate and immune function between the two groups(P<0.05).Conclusion Thymopentin combined with pemetrexed and cisplatin chemotherapy can significantly enhance the immune function of patients with advanced lung adenocarcinoma,which provides valuable reference for clinical practice.

关 键 词：胸腺五肽 化疗 晚期肺腺癌 免疫功能 

分 类 号：R734.2[医药卫生—肿瘤]